|Bid||14.25 x 1800|
|Ask||14.26 x 2900|
|Day's range||14.14 - 14.27|
|52-week range||13.05 - 17.31|
|Beta (5Y monthly)||0.80|
|PE ratio (TTM)||30.32|
|Forward dividend & yield||0.80 (5.65%)|
|Ex-dividend date||29 Sept 2021|
|1y target est||N/A|
TAK vs. ZTS: Which Stock Is the Better Value Option?
The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
It's been an ugly year in the stock market in 2022, and most investors are deep in the red. For instance, Immunocore (NASDAQ: IMCR) investors just had a U.S. Food and Drug Administration (FDA) approval, and that stock has shot higher with a 30% gain this year. Will Axsome Therapeutics (NASDAQ: AXSM) be the next stock to pop?